In a collaborative study published in The Lancet Microbe, the team of scientists, led by the Peter Doherty Institute for Infection and Immunity (Doherty Institute) and WEHI (Walter and Eliza Hall Institute of Medical Research), revealed MPXV-CRISPR – a powerful diagnostic tool capable of detecting MPXV in clinical samples with acute precision and at a faster rate than any other method, thanks to the power of CRISPR technology.
AnaptysBio touts PhIII win in a rare form of psoriasis. But it doesn’t plan on keeping the drug
AnaptysBio’s antibody for a rare form of psoriasis passed a Phase III study, but it’s still getting the boot, the company announced on Monday. After
October 10, 2023